NeoSoma

Nexus build production-ready AI agents without code for non-technical teams in large organizations.

Cara is a domain-specific AI platform purpose-built for insurance—a modular system that enables agencies, brokerages, and MGAs to automate servicing, accelerate sales, and scale operations with a 24/7 digital workforce.

Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions. Its platform includes Sage, an AI care assistant that works alongside human clinicians to provide reminders, practice exercises, and emotional support while following clinical guidance. Sage collects patient interactions, escalates critical situations, and shares progress with clinicians to inform ongoing care decisions. The system integrates evidence-based practices and measurement-based care into its AI workflows, maintaining clinician oversight and control over treatment strategies. It supports personalized behavioral health interventions by adapting to individual patient needs while ensuring privacy and security. Jimini Health’s approach combines human clinical expertise with AI-driven engagement, aiming to enhance patient adherence, monitor progress, and support consistent behavioral health care outside traditional session times.

NomadicML develops visual reasoning AI Agents for Autonomous Systems

Zapdos Labs build AI video agents for manufacturing and defense. It turns existing cameras and machine data into AI video agents that detect safety, quality, and operational issues before they become costly. The platform is built to shorten iteration cycles for computer-vision-based workflows, with GPU-native deployment, sub-second alerts, and support for both telemetry and CCTV inputs. This lets manufacturers deploy faster, test new workflows quickly, and improve models and rules directly in production environments.

Promaxo is a medical tech company that creates and sells patient-focused MRI systems and robotics that work in tandem with MRI machines, along with machine learning technologies. Their aim is to improve patient outcomes and change the way healthcare is delivered. They have developed unique technologies protected by numerous patents and are introducing the first in-office MRI and robotics guidance system. They are also working on new products such as disposable items and a system for characterizing tissue using artificial intelligence.

Sycamore provides an operating system for enterprises to build, deploy, and manage autonomous AI agents. The platform enables organizations to generate production-ready applications, integrations, and agents from natural language input while maintaining oversight and security. Agents operate under a progressive trust framework, allowing them to gain autonomy based on performance, with all actions being auditable and governed. The system captures organizational knowledge and supports continuous learning, enabling multi-agent coordination and adaptation over time. It integrates security, compliance, and governance features to ensure controlled and traceable operations. Sycamore also facilitates experimentation with agent behavior, safety, and meta-learning to improve enterprise workflows through automated intelligence.

Fermi America develops large-scale energy and AI infrastructure through its flagship HyperGrid™ Project, also known as the Advanced Energy and Intelligence Campus. Located near Amarillo, Texas, the 5,800-acre site delivers a private grid designed to power some of the world’s largest AI data centers. The project integrates nuclear, natural gas, solar, wind, and battery storage to provide up to 11 gigawatts of IT capacity—enough energy to support millions of homes. Its services include building and operating modular, secure, and diversified energy systems tailored to the needs of high-performance computing and AI workloads. Fermi America provides advanced nuclear power solutions with Westinghouse AP1000 reactors, natural gas-fired combined-cycle plants, and renewable generation to ensure a constant and reliable supply. It also offers large-scale data center development with more than 18 million square feet of AI computing space, supported by modular energy storage systems for efficiency and resilience. Through its partnerships with leading engineering and construction firms, as well as suppliers of advanced nuclear and energy technologies, Fermi America positions itself as a key provider of next-generation infrastructure that combines energy innovation with artificial intelligence at an unprecedented scale.

At CredX.AI, we believe investing should be driven by financial insight, not fine print. Yet corporate loan documents are long, complex, and notoriously opaque—and a single misunderstood clause can slash principal recoveries by 40% or more during a restructuring. That’s why we’re offering the Covenant Intelligence Platform: AI that transforms dense legal language into actionable intelligence. Our platform empowers hedge fund analysts to screen, compare, and select high-yield debt opportunities faster, by uncovering the hidden signals buried deep in loan contracts. Want a free demo? Email us at demo@credx.ai

Phonely is an AI receptionist that answers the phone like a person

Stratum Biosciences is a biotechnology company that develops and commercializes advanced wound care and regenerative medicine products derived from human tissue. The company focuses on solutions that support healing for burns, chronic wounds, and surgical applications, using biologically active materials to promote tissue repair. Its product portfolio typically includes skin substitutes and amniotic membrane-based therapies designed to improve clinical outcomes and reduce recovery time. Stratum Biosciences serves healthcare providers such as hospitals, clinics, and surgical centers, offering products that integrate into existing treatment protocols. The company operates within the broader regenerative medicine sector, emphasizing innovation, quality standards, and compliance with healthcare regulations.

Sinopia Biosciences is transforming the way disease research and drug discovery are conducted. While target-based drug discovery has been the primary method for the past thirty years, the complexity and unknown causes of many diseases have led to a shift towards phenotypic screening. This approach, which focuses on a limited number of specific indicators, has proven to be more effective in finding groundbreaking medications. Sinopia is utilizing advanced techniques such as high-throughput multi-omics data analysis, machine learning, and disease models to make data-driven drug discovery a reality.